Entering text into the input field will update the search result below

Synthetic Biologics inks deal with Cedars-Sinai Medical Center for clinical study of SYN-010 for the treatment of IBS-C

  • Synthetic Biologics (NYSE:SYN) has entered into an agreement with Cedars-Sinai Medical Center for an investigator-sponsored Phase 2 clinical study of SYN-010.
  • The study will further evaluate the efficacy and safety of SYN-010, a modified-release reformulation of lovastatin lactone, which is exclusively licensed by Cedars-Sinai Medical Center.
  • The 12-week, placebo-controlled Phase 2 study will evaluate two dose strengths of oral SYN-010 (21 mg and 42 mg) in ~150 patients diagnosed with IBS-C. The enrollment is expected to begin during Q4.
  • The primary objective is to determine the efficacy of both the doses of SYN-010, measured as an improvement from baseline in the weekly average number of complete spontaneous bowel movements (CSBMs) relative to placebo.
  • Secondary efficacy endpoints are to measure changes from baseline in abdominal pain, bloating, stool frequency as well as the use of rescue medication relative to placebo.
  • SYN-010 is designed to reduce methane production by certain microorganisms (M. smithii) in the gut to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C).
  • Shares are up 6% premarket.

Recommended For You

About TOVX Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
TOVX--
Theriva Biologics, Inc.